Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

To Evaluate the Efficacy and Safety of Anlotinib Combined With Allitinib in Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04671303
Recruitment Status : Not yet recruiting
First Posted : December 17, 2020
Last Update Posted : December 17, 2020
Sponsor:
Information provided by (Responsible Party):
Shi Yuankai, Chinese Academy of Medical Sciences

Brief Summary:
This Study is To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule Combined with Allitinib Tablets in First-line Treatment of Advanced no-squamous and No-small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation.

Condition or disease Intervention/treatment Phase
Lung Cancer Drug: Anlotinib Hydrochloride Capsule Combined with Allitinib Tablets Phase 2

Detailed Description:

This Study is To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule Combined with Allitinib Tablets in First-line Treatment of Advanced No-squamous and No-small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation.

This study is a single arm, phase II study, including 18 to 36 subjects; Common Terminology Criteria for Adverse Events 5.0 standard was used to evaluate adverse events of drugs, and Response Evaluation Criteria In Solid Tumors 1.1 was used to evaluated efficacy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: This Study is To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule Combined With Allitinib Tablets in First-line Treatment of Advanced No-small Cell Lung Cancer
Estimated Study Start Date : January 1, 2021
Estimated Primary Completion Date : September 30, 2021
Estimated Study Completion Date : September 30, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Experimental: Anlotinib Hydrochloride Capsule Combined with Allitinib Tablets

Anlotinib Hydrochloride Capsule: Oral on an empty stomach, once a day, 1 capsule each time, orally for 2 consecutive weeks, stop for 1 week Allitinib Tablets:The dose of allitinib mesylate is 80 mg once a day, 2 tablets each time, taken orally on an empty stomach before breakfast.

Take medicine continuously for 3 weeks (21 days) for 1 cycle.

Drug: Anlotinib Hydrochloride Capsule Combined with Allitinib Tablets

Anlotinib Hydrochloride Capsule: Oral on an empty stomach, once a day, 1 capsule each time, orally for 2 consecutive weeks, stop for 1 week Allitinib Tablets:The dose of allitinib mesylate is 80 mg once a day, 2 tablets each time, taken orally on an empty stomach before breakfast.

Take medicine continuously for 3 weeks (21 days) for 1 cycle.





Primary Outcome Measures :
  1. Safety and Efficacy of drug therapy [ Time Frame: up to 4 weeks ]
    The probability and severity of first cycle adverse events (AE) and serious adverse events (SAE) (based on Common Terminology Criteria for Adverse Events 5.0) and abnormal laboratory test indicators;


Secondary Outcome Measures :
  1. The overall efficacy was assessed by the investigators [ Time Frame: up to 48 weeks ]
    Objective response rate (ORR) assessed by the investigators



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Locally advanced and/or metastatic NSCLC diagnosed histologically and/or cytologically;
  2. Age 18 and above; Eastern Cooperative Oncology Group Physical condition: 0~1; The expected survival time is more than 3 months;
  3. Patients must present with a previously reported exon deletion mutation of Epidermal Growth Factor Receptor 19 .

    The investigator confirmed that the report could reflect the patient's current genetic status.

  4. There is at least one measurable lesion other than brain lesion defined by Response Evaluation Criteria In Solid Tumors 1.1 standard;
  5. The main organs are functioning well,Adequate laboratory indicators.
  6. Women of childbearing age should agree to use contraceptives during the study period and for a period of six months after the study; Negative serum or urine pregnancy test within 7 days prior to study inclusion, and must be non-lactating; Male patients should agree to use contraception during the study period and for six months after the end of the study period;
  7. Patients voluntarily participated in this study, signed informed consent, and had good compliance.

Exclusion Criteria:

  1. Prior history of targeted Epidermal Growth Factor Receptor therapy and anti-angiogenic drugs
  2. Received chemical or biological drugs after the diagnosis of advanced stage;
  3. Subjects had undergone surgery , radiation therapy or other anticancer therapies within 4 weeks prior to the commencement of study treatment; Subjects who have previously received local radiation therapy may be enrolled if the following conditions are met: more than 4 weeks after the end of radiation therapy ;
  4. Within 2 weeks before the start of the study, patients were treated with Chinese medicines
  5. Imaging shows that the tumor has invaded the periphery of important blood vessels or the investigator has determined that the tumor is very likely to invade important blood vessels and cause fatal bleeding during the follow-up study.
  6. Uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage ;
  7. Brain metastases with symptoms or symptom control time less than 2 weeks;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04671303


Contacts
Layout table for location contacts
Contact: Yuankai S, Doctor 010-87788268 medart@126.com

Sponsors and Collaborators
Chinese Academy of Medical Sciences
Investigators
Layout table for investigator information
Principal Investigator: Yuankai S, Doctor Chinese Academy of Medical Sciences and Peking Union Medical College
Layout table for additonal information
Responsible Party: Shi Yuankai, Director, Chinese Academy of Medical Sciences
ClinicalTrials.gov Identifier: NCT04671303    
Other Study ID Numbers: ALTN-AFTN-II-01
First Posted: December 17, 2020    Key Record Dates
Last Update Posted: December 17, 2020
Last Verified: December 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases